Marban Linda 4
4 · CAPRICOR THERAPEUTICS, INC. · Filed Feb 14, 2020
Insider Transaction Report
Form 4
Marban Linda
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Award
Stock Option (Right to Buy)
2020-02-12+25,000→ 25,000 totalExercise: $1.39Exp: 2029-08-08→ Common Stock (25,000 underlying) - Award
Stock Option (Right to Buy)
2020-02-12+9,998→ 9,998 totalExercise: $1.39Exp: 2028-01-02→ Common Stock (9,998 underlying) - Award
Stock Option (Right to Buy)
2020-02-12+19,999→ 19,999 totalExercise: $1.39Exp: 2027-01-03→ Common Stock (19,999 underlying) - Award
Stock Option (Right to Buy)
2020-02-12+25,000→ 25,000 totalExercise: $1.39Exp: 2025-03-03→ Common Stock (25,000 underlying) - Award
Stock Option (Right to Buy)
2020-02-12+41,497→ 41,497 totalExercise: $1.39Exp: 2023-05-14→ Common Stock (41,497 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-02-12−25,000→ 0 totalExercise: $3.25Exp: 2029-08-08→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-02-12−9,998→ 0 totalExercise: $15.70Exp: 2028-01-02→ Common Stock (9,998 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-02-12−19,999→ 0 totalExercise: $25.50Exp: 2027-01-03→ Common Stock (19,999 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-02-12−25,000→ 0 totalExercise: $57.80Exp: 2025-03-03→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-02-12−41,497→ 0 totalExercise: $3.00Exp: 2023-05-14→ Common Stock (41,497 underlying)
Footnotes (5)
- [F1]5,000 of the shares were vested on the date of grant. The remaining 20,000 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.
- [F2]The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.
- [F3]6,647 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 3,351 shares will vest 1/12th on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.
- [F4]The shares will vest 1/48th on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.
- [F5]The stock option award is fully vested and exercisable.